drugset / Trial / NCT07325500
Incretin Microdosing for Cardiometabolic Health in People With HIV
Phase 2
Recruiting
30 enrolled
The University of Texas Health Science Center, Houston
Massachusetts General Hospital (MGH) · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabUniversity of Colorado Denver - Anschutz Medical Campus (UCD-AMC) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The objectives of this study are as follows: Primary Objective * To determine the rate of weight regain in people living with human immunodeficiency virus (HIV) (PWH) receiving semaglutide microdosing vs. no additional drug following induction therapy. Secondary Objectives * To evaluate the tolerability of semaglutide microdosing in adults with HIV. * To evaluate changes in weight, waist circumference (WC) and body mass index (BMI) over 12 weeks (W) of semaglutide weight loss induction and 48 W of semaglutide microdosing therapy.
Timeline
- Start
- 2026-02-12
- Primary completion
- 2028-05-31
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Semaglutide | Peptide | 0.5 mg | Subcutaneous |
Indications
No indication recorded.